499 related articles for article (PubMed ID: 23616953)
21. Real-life Experience With Ponatinib in Chronic Myeloid Leukemia: A Multicenter Observational Study.
Shacham-Abulafia A; Raanani P; Lavie D; Volchek Y; Ram R; Helman I; Shargian L; Gourevitch A; Chubar E; Ratzon R; Rozovski U
Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):e295-e301. PubMed ID: 29773429
[TBL] [Abstract][Full Text] [Related]
22. Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation.
Nicolini FE; Basak GW; Kim DW; Olavarria E; Pinilla-Ibarz J; Apperley JF; Hughes T; Niederwieser D; Mauro MJ; Chuah C; Hochhaus A; Martinelli G; DerSarkissian M; Duh MS; McGarry LJ; Kantarjian HM; Cortes JE
Cancer; 2017 Aug; 123(15):2875-2880. PubMed ID: 28387926
[TBL] [Abstract][Full Text] [Related]
23. Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study.
Heiblig M; Rea D; Chrétien ML; Charbonnier A; Rousselot P; Coiteux V; Escoffre-Barbe M; Dubruille V; Huguet F; Cayssials E; Hermet E; Guerci-Bresler A; Amé S; Sackmann-Sala L; Roy L; Sobh M; Morisset S; Etienne G; Nicolini FE
Exp Hematol; 2018 Nov; 67():41-48. PubMed ID: 30195076
[TBL] [Abstract][Full Text] [Related]
24. Ponatinib-Induced Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia without the T315I Mutation Relapsing after Allogeneic Transplant.
Petrungaro A; Gentile M; Mazzone C; Greco R; Uccello G; Recchia AG; De Stefano L; Bossio S; Palummo A; Morelli R; Musolino C; Morabito F; Vigna E
Chemotherapy; 2017; 62(6):353-356. PubMed ID: 28810255
[TBL] [Abstract][Full Text] [Related]
25. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
[TBL] [Abstract][Full Text] [Related]
26. [Ponatinib: new option for the treatment of resistant chronic myeloid leukemia].
Camañas-Troyano C; Calderón-Acedos C; Moriel-Sánchez Mdel C; Segura-Bedmar M
Farm Hosp; 2013; 37(5):428-9. PubMed ID: 24128110
[No Abstract] [Full Text] [Related]
27. A personalised medicine approach for ponatinib-resistant chronic myeloid leukaemia.
Korfi K; Mandal A; Furney SJ; Wiseman D; Somervaille TCP; Marais R
Ann Oncol; 2015 Jun; 26(6):1180-1187. PubMed ID: 25712455
[TBL] [Abstract][Full Text] [Related]
28. The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib.
Parker WT; Yeung DT; Yeoman AL; Altamura HK; Jamison BA; Field CR; Hodgson JG; Lustgarten S; Rivera VM; Hughes TP; Branford S
Blood; 2016 Apr; 127(15):1870-80. PubMed ID: 26773037
[TBL] [Abstract][Full Text] [Related]
29. PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation.
Mian AA; Rafiei A; Haberbosch I; Zeifman A; Titov I; Stroylov V; Metodieva A; Stroganov O; Novikov F; Brill B; Chilov G; Hoelzer D; Ottmann OG; Ruthardt M
Leukemia; 2015 May; 29(5):1104-14. PubMed ID: 25394714
[TBL] [Abstract][Full Text] [Related]
30. Ponatinib in Philadelphia chromosome-positive leukemias.
Quintas-Cardama A
N Engl J Med; 2014 Feb; 370(6):577. PubMed ID: 24499222
[No Abstract] [Full Text] [Related]
31. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of ponatinib against ABL tyrosine kinase inhibitor-resistant leukemia cells.
Okabe S; Tauchi T; Tanaka Y; Ohyashiki K
Biochem Biophys Res Commun; 2013 Jun; 435(3):506-11. PubMed ID: 23684619
[TBL] [Abstract][Full Text] [Related]
33. Further Analytical, Pharmacokinetic, and Clinical Observations on Low-Dose Ponatinib in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
Menna P; De Grazia U; Marchesi F; Minotti G; Salvatorelli E
Chemotherapy; 2020; 65(1-2):35-41. PubMed ID: 32829325
[TBL] [Abstract][Full Text] [Related]
34. Axitinib in Ponatinib-Resistant B-Cell Acute Lymphoblastic Leukemia Harboring a T315L Mutation.
Giudice V; Ghelli Luserna di Rorà A; Serio B; Guariglia R; Giannini MB; Ferrari A; Simonetti G; Selleri C; Martinelli G
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33419251
[TBL] [Abstract][Full Text] [Related]
35. Ponatinib--a step forward in overcoming resistance in chronic myeloid leukemia.
Frankfurt O; Licht JD
Clin Cancer Res; 2013 Nov; 19(21):5828-34. PubMed ID: 23935038
[TBL] [Abstract][Full Text] [Related]
36. Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee.
Januzzi JL; Garasic JM; Kasner SE; McDonald V; Petrie MC; Seltzer J; Mauro M; Croce K; Berman E; Deininger M; Hochhaus A; Pinilla-Ibarz J; Nicolini F; Kim DW; DeAngelo DJ; Kantarjian H; Xu J; Hall T; Srivastava S; Naranjo D; Cortes J
J Hematol Oncol; 2022 Jan; 15(1):1. PubMed ID: 34991679
[TBL] [Abstract][Full Text] [Related]
37. Ponatinib vs Imatinib in Frontline Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
Jabbour E; Kantarjian HM; Aldoss I; Montesinos P; Leonard JT; Gómez-Almaguer D; Baer MR; Gambacorti-Passerini C; McCloskey J; Minami Y; Papayannidis C; Rocha V; Rousselot P; Vachhani P; Wang ES; Wang B; Hennessy M; Vorog A; Patel N; Yeh T; Ribera JM
JAMA; 2024 Jun; 331(21):1814-1823. PubMed ID: 38722621
[TBL] [Abstract][Full Text] [Related]
38. The multi-tyrosine kinase inhibitor ponatinib for chronic myeloid leukemia: Real-world data.
Luciano L; Annunziata M; Attolico I; Di Raimondo F; Maggi A; Malato A; Martino B; Palmieri F; Pane F; Sgherza N; Specchia G
Eur J Haematol; 2020 Jul; 105(1):3-15. PubMed ID: 32145037
[TBL] [Abstract][Full Text] [Related]
39. Molecular remission after combination therapy with blinatumomab and ponatinib with relapsed/refractory Philadelphia chromosome-positive acute lymphocytic leukemia: two case reports.
Yuda J; Yamauchi N; Kuzume A; Guo YM; Sato N; Minami Y
J Med Case Rep; 2021 Mar; 15(1):164. PubMed ID: 33762010
[TBL] [Abstract][Full Text] [Related]
40. BCR-ABL1 compound mutations drive ponatinib resistance.
Cancer Discov; 2014 Nov; 4(11):OF13. PubMed ID: 25367954
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
